Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

facturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of ST-246 and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty when SIGA will commence delivering any product or will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore, the Court of Chancery may grant SIGA's motion for reargument and the Court of Chancery decision could be appealed by SIGA, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, to the extent that there is an appeal, we cannot predict how long that will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax ™, Valortim® and our rBChE product. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com. -- Tables Follow --PHARMATHENE, INC.CONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,December 31,2011Unaudited2010ASSETSCurrent assets:Cash and cash equivalents$

10,406,076$

11,785,327Restricted cash100,000100,000Accounts receivable, net4,039,7015,367,130Other re
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 CIO Review ( http://www.cioreview.com ... 20 Most Promising Pharma and Life Science Technology Solution ... global compliance software platform for life sciences companies. ... a panel of experts and members of CIO Review’s ... MediSpend Platform has been on our radar for some ...
(Date:4/17/2015)... 17, 2015 LC Sciences LLC, ... announced today that it is seeking beta testers ... multiplex PCR based targeted sequencing technology. The system ... that enables accurate detection of rare variants. It ... technologies. The company will collaborate with beta testers ...
(Date:4/16/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... results on Thursday, April 30, 2015 at 4:00 PM ... host a conference call at 4:30 PM Eastern Time ... outlook for the future. , The conference call will ... homepage and in the Investor Relations section of Cytokinetics’ ...
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... ROCKVILLE, Md., Jan. 26 Neuralstem, Inc. (NYSE ... received Official Notice of Allowance for its patent ... Lines from the US Patent and Trade Office ... any human neural stem cell, rendering its growth ...
... Ireland, January 26 ICON plc, (NASDAQ:, ... development,services to the pharmaceutical, biotechnology and medical device ... solution that will accelerate,the adjudication of cardiovascular events ... The evaluation of cardiovascular risk in diabetic trials ...
... a new marketing "mashup" that integrates web ... the sole purpose of generating leads, today ... ChemBridge Corp., a leader in discovery chemistry ... biotech and research institutions. ChemBridge will retain ...
Cached Biology Technology:Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 2Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 3ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication 2ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication 3HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge 2HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge 3HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge 4
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... been found to rely on a wide range of ... soil instead of producing their own organic carbon. A ... access journal BMC Biology , also features stunning ... Roy, from the Centre d,Ecologie Fonctionnelle et Evolutive, Montpellier, ...
... circovirus associated diseases cost pig producers around the world ... why Kansas State University virologists Dick Hesse and Bob ... tackle such complex diseases. "Circovirus and its associated ... "Both porcine reproductive and respiratory syndrome and circovirus are ...
... 2009 - The International Myeloma Foundation (IMF)supporting research and ... researchers and physicianstoday said newly published data may provide ... disease in multiple myeloma. Myeloma, also called multiple myeloma, ... that affect production of blood cells and can damage ...
Cached Biology News:K-State lab gives researchers the tools to study porcine circovirus associated diseases 2New study suggests possible genetic links between environmental toxins and multiple myeloma 2
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
ANTI S. ENT TOX BC2D...
... Anti-Major DNA-binding protein(DBP). Protein size: ... NP_001343 ELISA titre using peptide ... conditions for Western Blot: 1.0g/ml ... and HRP conjugated anti-Rabbit IgG should be ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: